近日,默沙东在公布2025第二季业绩的同时,更新了其管线信息。与第一季度相比,多个II期和III期临床管线被终止,其中包括MK-1308(CTLA-4单抗)针对非小细胞肺癌的II期研究、MK-6194(IL-2融合蛋白)针对红斑狼疮和白癜风的II期研究、MK-1022(HER3-ADC)针对非小细胞肺癌的III期研究,以及MK-7902(仑伐替尼)针对食管癌的III期研究。默沙东第一季度管线MK-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.